Q2 2024 |
252 |
$553M |
+$73.2M |
-$57.3M |
+$15.9M |
IBD, GLRY, WWJD, AGZ, BITO
|
13F-HR |
8/14/2024, 02:59 PM |
Q1 2024 |
251 |
$551M |
+$82M |
-$21.1M |
+$60.9M |
IBD, IBTE, GLRY, BITO, WWJD
|
13F-HR |
5/15/2024, 02:40 PM |
Q4 2023 |
255 |
$440M |
+$41.8M |
-$44M |
-$2.23M |
IBD, IBTE, GLRY, WWJD, BITO
|
13F-HR |
2/14/2024, 05:31 PM |
Q3 2023 |
247 |
$394M |
+$35.3M |
-$44.5M |
-$9.17M |
IBD, GLRY, WWJD, IBTE, SCHQ
|
13F-HR |
11/14/2023, 07:58 PM |
Q2 2023 |
268 |
$433M |
+$25.6M |
-$49.9M |
-$24.2M |
SCHQ, GLRY, IBD, WWJD, BITO
|
13F-HR |
8/14/2023, 06:36 PM |
Q1 2023 |
308 |
$432M |
+$78.7M |
-$123M |
-$44.5M |
IBD, GLRY, SCHQ, WWJD, IVOL
|
13F-HR |
5/15/2023, 05:08 PM |
Q4 2022 |
266 |
$460M |
+$134M |
-$115M |
+$18.9M |
GLRY, IBD, SCHQ, WWJD, TPLC
|
13F-HR |
2/14/2023, 02:26 PM |
Q3 2022 |
236 |
$422M |
+$121M |
-$119M |
+$1.92M |
IBD, TPLC, WWJD, VGSH, IVOL
|
Restatement |
11/18/2022, 09:25 AM |
Q2 2022 |
254 |
$446M |
+$42.3M |
-$33.5M |
+$8.84M |
IBD, FEVR, BIBL, GLRY, IEF
|
13F-HR |
8/12/2022, 01:13 PM |
Q1 2022 |
268 |
$514M |
+$33.8M |
-$14.6M |
+$19.2M |
IBD, FEVR, IVOL, BIBL, GLRY
|
13F-HR |
5/16/2022, 12:30 PM |
Q4 2021 |
265 |
$524M |
+$106M |
-$100M |
+$5.98M |
IBD, FEVR, BIBL, IVOL, GLRY
|
13F-HR |
2/14/2022, 05:21 PM |
Q3 2021 |
277 |
$514M |
+$37.7M |
-$22.4M |
+$15.4M |
IBD, FEVR, IVOL, GLRY, PDBC
|
13F-HR |
11/15/2021, 05:44 PM |
Q2 2021 |
264 |
$505M |
+$145M |
-$121M |
+$23.8M |
IBD, FEVR, IVOL, GLRY, PDBC
|
13F-HR |
8/13/2021, 05:37 PM |
Q1 2021 |
238 |
$447M |
+$254M |
-$39.5M |
+$214M |
IBD, IEI, GLRY, IEF, FEVR
|
13F-HR |
5/13/2021, 04:17 PM |
Q4 2020 |
119 |
$229M |
+$56.2M |
-$257M |
-$201M |
IBD, GLRY, FEVR, WWJD, VMBS
|
13F-HR |
2/16/2021, 06:04 PM |
Q3 2020 |
212 |
$413M |
+$113M |
-$103M |
+$10.7M |
IEI, IBD, IEF, WWJD, TPLC
|
13F-HR |
11/13/2020, 09:37 AM |
Q2 2020 |
206 |
$385M |
+$113M |
-$126M |
-$12.6M |
IEF, TPLC, WWJD, VMBS, SHY
|
13F-HR |
8/13/2020, 10:49 AM |
Q1 2020 |
236 |
$355M |
+$100M |
-$101M |
-$1.21M |
IEF, TPLC, ISMD, VMBS, JPMF
|
13F-HR |
5/11/2020, 09:20 PM |
Q4 2019 |
240 |
$425M |
+$199M |
-$248M |
-$48.8M |
TPLC, ISMD, IEF, TIP, RINF
|
13F-HR |
1/22/2020, 04:40 PM |
Q3 2019 |
101 |
$452M |
$0 |
$0 |
|
RINF, ISMD, BLES, IBD, LEMB
|
13F-HR |
11/14/2019, 07:02 PM |